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Abstract
Background: Human papillomavirus (HPV) currently represents an important risk factor for cancer development
and infertility in humans. Whilst binding of HPV to spermatozoa has been associated with male infertility, an
investigation about the presence of HPV-DNA in non-spermatozoal semen cells is lacking. Previous findings
documented the presence of HPV in peripheral blood leukocytes. The aim of this study was to investigate the
expression of HPV markers in semen and blood leukocytes during HPV-16 infection.
Methods: A total of 32 subjects, 16 patients affected by HPV-16 semen infection and 16 controls, were evaluated in
our andrological centre and enrolled in the study. Semen non-spermatozoal cells from all subjects were isolated
and evaluated for the expression of HPV-16 markers (DNA and L1, E6 proteins) and further characterized for their
molecular phenotype. Analogue determination was performed on peripheral blood mononuclear cells.
Results: The presence of HPV-DNA by FISH analysis in a round cell population from semen, confirmed to be CD45+
leukocytes, was observed. These HPV-DNA containing-cells also displayed HPV-16-E6 and HPV-16-L1 viral proteins
and, upon further investigation, were found to be CD20+ and CD56+, likely phenotypes of B cells and natural killer
cells (NK) respectively. In 25% of the patient group, a very small population of peripheral blood mononuclear cells
was found to be positive for HPV-DNA via FISH. These cells displayed the CD20+ and CD56+ phenotype alike. None
of the control subjects displayed HPV-DNA in either semen or peripheral blood.
Conclusion: Considering the role of CD20+ and CD56+ cell populations in the antiviral immune response, the
detection of HPV markers on leukocytes may reflect the presence of virus particles within the endosomal
compartment. However, the presence of HPV markers in circulating mononuclear cells raise concerns about the risk
of developing cancers to distal organs.
Keywords: Human papillomavirus, Semen infection, Fluorescence in situ hybridization, Peripheral blood
mononuclear cells, Hpv-related disease
Background
Once considered a sexually transmitted virus principally
affecting females, human papillomavirus (HPV) currently
represents an important factor responsible for both couple
infertility and cancer development, as demonstrated by
recent experimental and epidemiological data [1]. Cervical
cancer is the most common cause of mortality related to
human papillomavirus [1] but HPV infection also raises
important concerns for men. In fact, HPV has been associ-
ated with most male anal cancers (approximately 90%) and
a subset of penile (50%) and oral cancers (10–72%) [2].
Additionally, the presence of HPV has been widely reported
in semen [3], where it has been associated with impairment
of sperm motility [4], supporting the hypothesis that HPV
infection is an emerging risk factor for male infertility.
Previous studies from our group have documented that
HPV can be detected in different cell populations
within human semen. By the use of fluorescence in situ
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hybridization (FISH) analysis, HPV-DNA has been detec-
ted on both sperm and non-spermatozoal cells [5-7].
These latter include Sertoli cells, squamous epithelial
cells and ‘round cells’, such as spermatozoal precursors,
erythrocytes and leukocytes [8]. While the presence of
Sertoli, immature sperm and epithelial cells is generally
considered the result of natural cell turnover and epithelial
exfoliation, the presence of increased levels of sperm
leukocytes has been traditionally associated with con-
comitant inflammation or infection of the genito-
urinary tract [9]. However, the detection of HPV-DNA
in non-spermatozoal cells has not been further investi-
gated. Recent findings from our lab showed that male
patients with HPV 16 in semen had a round shaped
subpopulation of cells positive for FISH-HPV, not
morphologically ascribable to spermatozoa or epithelial
cells. A cytological analysis with May Grunwald-Giemsa
staining suggested these cells to be of myeloid origin and
subsequent cytochemical analysis confirmed the popula-
tion to be CD45-positive leukocytes. Despite no clear
tropism of HPV to white blood cells has been demon-
strated, this observation is in agreement with previous
reports showing papillomavirus-DNA associated with
circulating leukocytes in both human and animal models
[10-12]. The possible access of papillomavirus to periph-
eral blood leukocytes has been very recently strenghtened
by experimental data from animal models, showing that
BPV-DNA and transcripts can be found in blood cells a
few days after intradermal inoculation of horses with BPV1
[13]. Moreover in humans, several studies conducted in
female patients with cervical cancers, have shown that HPV
DNA can be found in peripheral blood, sera, plasma and
arterial cord blood [14,15]. In these studies, authors con-
cluded that HPV detected in blood cells of cancer patients
was not, or not-only, subtended by metastatic cells released
at a later stage of disease but was also associated to blood
mononuclear cells. Moreover, circulating HPV DNA was
detected also in healthy blood donors [11]. However, the
vast majority of these studies did not show HPV inside
blood cells. Most or all of the studies merely focused on the
expression of HPV DNA in blood, or on the outside surface
of cells [11]. This latter aspect, prompted us to consider
HPV infection as a triggering event for virus diffusion into
blood stream, even in the absence of evident HPV related
diseases. The aim of the present study was to better
characterize HPV infected round cells in semen and to




The study conformed with the principles outlined in
the Declaration of Helsinki and was approved by the
Institutional Ethics Committee of the Padua General
Hospital by Protocol No.2336. All participants pro-
vided written informed consent.
Sixteen male patients (mean age 38.8 ± 9.8), attending
our Centre for infertility evaluation, were consecutively
enrolled in the study on the basis of the detection of
HPV-16 in the genito-urinary tract. More precisely, semen
samples from patients were formerly assessed for the
presence of HPV-DNA on sperm and/or non-spermatozoal
cells by FISH analysis. Successively, patients underwent
HPV genotyping, performed by INNO LiPA analysis [16],
on uretral/coronal sulcus brushing specimens and whole
semen samples. Positivity to the sole HPV-16 allowed the
enrollment as patients. Exclusion criteria were; history of
cryptorchidism, testicular trauma, post-mumps orchitis,
HPV-genotype other than HPV-16, presence/history
of varicocele or the presence of other urinary/seminal
infections detected by testicular Doppler ultrasound
and microbiological culture respectively.
Sixteen male partners of infertile couples (mean age
37.5 ± 5.9), negative for any type of HPV infection to
genito-urinary as defined above, were recruited as a
control group. Peripheral blood samples were collected
from every subject evaluated; each sample was assessed
for the presence of HPV-DNA as described below.
Semen sample collection and analysis
Semen samples were obtained by masturbation after
2–5 days of sexual abstinence and stored in sterile con-
tainers. Samples were allowed to liquefy for 30 minutes
before the evaluation of semen volume, pH, sperm
concentration, viability, motility, and morphology accord-
ing to World Health Organization guidelines for semen
analysis [17]. Anti-sperm antibodies were detected using
the spermMar test kit for IgG and IgA (FertiPro) as
described elsewhere [18].
Semen processing and round cells isolation
For each subject, isolation of semen round cells was
performed by density gradient centrifugation using an
Isolate Sperm Separation kit (Irvine Scientific, Santa Ana,
CA, USA) according to manufacturer’s instructions. After
centrifugation, cells from the upper layer were successively
collected, washed in PBS, centrifuged at 300 g for 10 min
at room temperature, fixed in 4% paraformaldehyde/PBS
solution for 15 min at room temperature, smeared on
SuperFrost®Plus glass slides (Menzel Glaser, Braunschweig,
Germany), air dried and finally stored at −20°C until
further analysis.
Peripheral blood sampling, processing and peripheral
blood mononuclear cell isolation
Peripheral blood samples from HPV16 infected
patients and control subjects were drawn from the
anterocubital vein in 3 ml Vacutainer-EDTA coated
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tubes (BD Biosciences, Milano, Italy). For each subject,
mononucelar cells from peripheral blood were isolated by
density gradient centrifugation on Ficoll Paque Plus (GE
Healthcare, Milano, Italy), washed twice in PBS and
centrifuged at 300 g for 10 min at room temperature and
the pellet was divided in two equal samples. A sample was
stored at – 20°C and used for further DNA extraction and
PCR analysis. The other sample was fixed in 4% parafor-
maldehyde/PBS solution for 15 min at room temperature,
smeared on SuperFrost®Plus glass slides, air dried and fi-
nally stored at −20°C until further analysis.
Fluorescence in situ hybridization (FISH) for HPV-DNA
Smears of semen round cells and of peripheral blood
mononuclear cells, previously fixed in paraformaldehyde
were analyzed. To permeabilize cells, samples were
digested with pepsin, diluted 1:25,000 in pre-warmed
0.01 mol/L HCl at 37°C. Permeabilization was stopped
following 3 to 5 minutes of treatment by rinsing in PBS.
Samples were dehydrated in 70% and 100% ethanol for
2 minutes each and finally air dried.
Permeabilized samples were overlaid with 20 μL of
hybridization solution containing a biotin-labeled HPV-
DNA probe (a mix of total genomes of 7–8 Kb, con-
taining the conserved HPV region, Pan Path, Amsterdam,
Netherlands). Each slide was covered with a glass coverslip
and the edges were sealed with silicone glue to prevent loss
of the mixture during denaturation and hybridization.
Following simultaneous denaturation of cellular target
DNA and the HPV DNA probe for 5 minutes at 95°C,
hybridization was performed by incubating the samples at
37°C overnight in a humidified chamber. Thereafter, the
coverslips were carefully removed and the slides were
washed in PBS for 10 minutes. The slides were incubated
at 37°C for 15 minutes with the differentiation reagent
(Pan Path), and washed 3 times in PBS. The biotin-labeled
HPV probe was detected by incubation with 1:200
streptavidin Texas Red® (Vector Laboratories, Burlingame,
CA) for 40 minutes at room temperature. After detection,
the slides were washed twice in PBS/0.01% Triton and then
twice in PBS and mounted with a solution containing
5 mg/mL of 4′,6-diamidino-2phenylindole (DAPI) and
anti-fade buffer (BioBlue, BioView Ltd., Nes Ziona, Israel).
Samples were analyzed using a fluorescence microscope
(Nikon ViCo Video Confocal Microscope). For each slide,
at least 1000 cells were analyzed. Evaluation of nuclear
hybridization signals was performed in triplicate by
different investigators. Positive control for HPV-DNA
staining, performed on Caski cell line infected with
HPV-16, are reported in Additional file 1: Figure S1A.
PCR amplification of HPV DNA in human mononuclear cells
Isolated mononuclear cells from peripheral blood under-
went DNA extraction by the use of a QIAamp DNA mini
kit (QIAGEN, Milano, Italy), according to the manufac-
turer’s instructions. Briefly, sample lysis was obtained
following proteinase K digestion at 56°C for 10 min, and
the lysates were then loaded on QIAamp columns. After
two washes, DNA was eluted with 200 μl of elution buffer.
Extracted DNA was kept at −80°C until analysis.
HPV-DNA detection was performed using an Ampli-
quality HPV-TYPE express kit® (AB Analitica, Padua, Italy)
according to the manufacturer’s protocol. The declared
detection limit of the assay was ≤ 500 viral copies/reaction
and the diagnostic sensitivity was 97,8%.
Immunofluorescence
Semen round cells and peripheral blood mononuclear
cells were analysed as follows. Specimens were treated
for 10 min with 1% Triton X-100 (Sigma Aldrich, Milano,
Italy) and saturated with 5%BSA-5% Normal Donkey
Serum/PBS for 30 min at room temperature. Samples were
incubated overnight at 4°C with goat anti-HPV-16 L1 anti-
body (2 μg/mL), or goat-anti HPV-16 E6 (2 μg/mL) (both
from Santa Cruz Biotechnology, Heidelberg, Germany)
and/or mouse anti-human CD45, or CD15 or CD4, or
CD8, or CD20, or CD56 immunoglobulins (0.4 μg/mL) (all
from BD Biosciences). For negative controls, primary
antibodies were omitted. Primary immunoreaction was
detected following incubation with the appropriate
secondary reagent for 60 minutes at room temperature
[biotin-conjugated anti-goat antibody and FITC-conjugated
anti-mouse antibody, Streptavidin-TexasRed treatment (all
1 μg/mL)]. Samples were finally counterstained with DAPI
and mounted in antifade-buffer. Slides were analyzed
with a Video-Confocal (VICO) fluorescence microscope
(Nikon, Firenze, Italy). Evaluation of nuclear hybridization
signals was performed in triplicate by different investiga-
tors. Positive controls staining for HPV-E6 and L1 pro-
teins, performed on Caski cell line infected by HPV-16,
are reported in Additional file 1: Figure S1A. Positive
control staining for human CD45, CD4, CD8, CD20 and
CD56, performed on isolated peripheral blood mono-
nuclear rells, are reported in Additional file 1: Figure
S1B.
Statistical analysis
Differences in seminal parameters between patients and
controls were evaluated by an unpaired two-sided Student’s
t-test. Comparisons between frequencies were performed
using the χ2 test.
Differences were considered significant when P < 0.05.
Variables are presented as mean ± SD.
Results
The seminal parameters of the HPV16-infected patients
and control subjects assessed are reported in Table 1.
We observed lower sperm motility and an increased
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frequency of positive SperMar test in HPV16-positive
samples. No significant differences in other seminal
parameters were observed between the two groups. FISH
analysis for HPV, performed on patient semen samples,
showed a 26.2 ± 5.9 mean percentage of HPV-DNA
bearing sperm. Among non-spermatozoal cells, we ob-
served a mean of 19.3 ± 8.4% HPV bearing cells. The
morphological features of these cells were clearly visible by
microscopy and were variable, ranging from large-irregular
shaped cells with disrupted nuclear margins of likely
epithelial origin, to round-regular shaped nucleated cells
with limited cytoplasm, possibly of the myeloid lineage
(Figure 1a I and II). No infected cells were observed in
semen samples from controls.
Analysis of semen round cells
No difference between the number of round cells was
found comparing the two groups (0.003 ± 0.002 103
cells/ml and 0.002 ± 0.001 103 cells/ml in infected and
non infected samples respectively, P > 0.05; Table 2).
In order to investigate the molecular phenotype of HPV
bearing cells, we enriched samples in round cells by
Table 1 Main sperm parameters and mean percentage of HPV infected cells assessed in semen samples from HPV-16



























19.8 ± 5.8 44.2 ± 15.8 108.9 ± 85.9 28.3 ± 14.3 * 37.5 * 26.2 ± 5.9 19.3 ± 8.4
Control (n = 16) 83.1 ± 7.5 19.1 ± 8.0 37.1 ± 9.1 115.1 ± 44.8 40.4 ± 16.8 6.3 0 0
Abbreviations: HPV: human papillomavirus.
Significance: * = p < 0.01 vs controls.
Figure 1 Analysis of HPV-16 markers in non-spermatozoal cells from semen samples. a: FISH analysis of HPV-16 DNA in non-spermatozoal
cells from semen samples. a I epithelial and a II non epithelial positive cells. Reference brigh-fiels pictures (BF) are added as inserts. b: FISH and
immunofluorescence analysis of HPV16-E6 or HPV16-L1 expression on HPV-DNA bearing non-spermatozoal cells. b I HPV16-E6 protein and b II
HPV16-L1 protein positive round cells.
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performing a density gradient centrifugation of whole
semen. The recovered number of semen round cells was
not quantitative and varied greatly within the cohort of
infected and non infected subjects. FISH analysis performed
on round cells detected HPV-DNA in all HPV 16 infected
samples; no specific signal was observed in controls. The
number of round cells displaying HPV-DNA varied from
10 to 40% among isolated cells. HPV-DNA was located
principally in the cytoplasm and less frequently in or over
the nucleus (Figure 1b I-II). Moreover, in almost all
HPV-DNA positive round cells, a signal for both E6- and
L1-HPV16 proteins was detected. Similar to HPV-DNA,
viral proteins were mainly located in the cytoplasm and less
frequently in the nucleus. An immunofluorescence assay
for CD45 and E6 expression performed on the same
specimens (Figure 2a) demonstrated that the vast majority
Table 2 Semen round cells concentration and molecular evaluation of HPV-DNA in semen and peripheral blood
mononuclear cells from HPV-16 semen infected and non infected subjects
Semen Blood
Sample number Round cells (x103/ml) Round cells FISH (+/−) PBMC FISH (+/−) PBMC HPV (+/−)
HPV 16 infected samples
1 0,002 + - -
2 0,002 + - -
3 0,001 + - -
4 0,001 + - -
5 0,002 + - -
6 0,003 + + +
7 0,001 + - -
8 0,001 + + +
9 0,005 + - -
10 0,005 + + +
11 0,004 + - -
12 0,003 + - -
13 0,003 + - -
14 0,001 + + -
15 0,003 + - -
16 0,004 + - -
Average 0,003 ± 0,001
Control samples
1 0,001 - - -
2 0,002 - - -
3 0,005 - - -
4 0,001 - - -
5 0,002 - - -
6 0,004 - - -
7 0,003 - - -
8 0,001 - - -
9 0,001 - - -
10 0,003 - - -
11 0,001 - - -
12 0,000 - - -
13 0,003 - - -
14 0,003 - - -
15 0,002 - - -
16 0,001 - - -
Average 0,002 ± 0,001
Abbreviations: FISH, Fluorescent in situ hybridization; HPV, Human Papillomavirus; PBMC, Peripheral Blood Mononuclear Cells; SB:
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(>95%) of E6-positive round cells were CD45-positive
leukocites [19]. Additional immunofluorescence assays
(Figure 2b I-II) on HPV-positive mononuclear cells
expressing the E6 protein, rarely or never displayed
staining for CD4 or CD8 cell markers. In contrast, specific
staining for CD20 or CD56 markers were found on 20%
and 70% of E6 positive cells respectively. Moreover, nearly
the 80% of semen CD56+/CD20+ leukocytes displayed
HPV16-E6 protein.
Analysis of peripheral blood leukocytes
The presence of HPV-DNA in peripheral blood mono-
nuclear cells (PBMC) was initially assessed by FISH. As
reported in Table 2, 4 patients out of 16 (25%) featured by
HPV-16 semen infection showed specific staining for
HPV-DNA in a very restricted population of PBMC
ranging from 0.1-0.6% (Figure 3a). In control subjects, the
presence of HPV-DNA in PBMC was never detected. In
parallel, the presence of HPV-DNA in peripheral blood
mononuclear cells was evaluated by PCR. Single-step PCR
analysis showed the presence of HPV-DNA in 3 out 4
PBMC samples showing HPV-DNA detected by FISH
(Figure 3b) None of controls showed positive reaction.
Further immunofluorescence analysis demonstrated that
HPV-DNA localised in the cytoplasm of positive cells
and co-localized with E6- and L1-HPV16 proteins in
almost all HPV-DNA-bearing cells (Figure 4a I-II). Finally,
the molecular phenotype of PBMC found to express HPV-
E6 protein was investigated by immunofluorescence. E6-
positive cells were found to co-express CD20 or CD56 in
35% and 60% of cases respectively (Figure 4b I-II). CD8 was
found to be expressed by 5% of E6 positive cells while in
none of the samples was found the co-expression of CD4
and E6 (data not shown).
Discussion
The results of this study have identified, for the first time,
the presence of HPV16 in CD45+ leucocytes in the semen
Figure 2 Immunophenotype of HPV16-bearing cells in semen round cells. a: Immunofluorescence analysis of HPV16-E6 and CD45
expression on semen round cells. b: Immunofluorescence assessment of HPV16-E6 and CD20, or CD56 expression on semen leukocytes.
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Figure 3 Analysis of HPV-DNA in peripheral blood mononuclear cells. a: FISH analysis of HPV-DNA in peripheral blood mononuclear cells.
b: PCR assessment of HPV-DNA in peripheral blood mononuclear cells from patients and controls. An example of HPV-DNA product
(139–145 kDa) detectable in patients 8 and 10 (Pt8 and Pt10 respectively) and undetectable in patients 5, 7 and 12 as well as in all control
subjects (Pt5, Pt7, Pt12, Ct1-5 respectively). Thiosulfate sulfurtransferase (TST) band at 202 kDa was used as an internal control.
Figure 4 Immunophenotype of HPV16-bearing cells in peripheral blood mononuclear cells. a: Immunofluorescence for HPV16-E6 and
HPV16-L1 proteins on peripheral blood mononuclear cells. a I HPV16-E6 and a II HPV16-L1 positive mononuclear cells. b: Immunofluorescence for
HPV16-E6 and CD20 or CD56 on peripheral blood mononuclear cells. b I HPV16-E6 and CD20 positive mononuclear cells. b II HPV16-E6 and
CD56 positive mononuclear cells.
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of infected patients. Furthermore, HPV was also detected
in a very restricted subpopulation of circulating PBMC
bearing a similar immunophenotype. Although these
findings are in contrast with the known tropism of HPV
for epithelial cells [20], other authors have reported HPV
spreading both from cancers and infected sites [10,20].
Pao et al. [21], first reported the presence of different types
of HPV [6,11,16,19] in peripheral blood mononuclear cells
from female patients affected by HPV infections of the
genito-urinary tract [21]. In addition, in a recent study
performed on HIV patients, 11 of 57 blood samples were
positive for HPV-16 DNA [14]. The authors stated that the
HPV genome detected in positive samples existed as an
episomal form, albeit at a low DNA copy number.
Moreover, in another study assessing a cohort of healthy
Australian blood donors, the presence of HPV-DNA in
peripheral leukocytes was reported in approximately 8% of
subjects [11]. Presence of circulating HPV can be explained
by the immune response. Local and systemic viral
infections are controlled by innate and adaptive
immune mechanisms, where both humoral responses,
which prevent disease recurrence [22], and cell-mediated
immune response are triggered. In particular for cell-
mediated immunity, NK cells together with CD1d-
restricted NK-T cells (iNKT cells) are the main cell
populations of the innate immune system responsible for
the clearance of HPV infection [23]. NK cells constitutively
express IFNγ, granzyme and perforin. They are ‘primed’ to
initiate an anti-viral immune response by detecting
decreased MHC-I expression on infected cells, in the case
of HPV, due to repression by the E5 and E7 viral-
oncoproteins at specific sites of the MHC-I processing and
presentation pathway [22-25]. In parallel, the activation of
antigen presenting cells (APC) and subsequent antigen
presentation in the draining lymph nodes is necessary
for the initiation of a primary adaptive response to an
infecting agent. In the case of HPV, the local APCs
responsible are the Langherhans cells of the epidermis,
dendritic cells present in the dermis, and occasionally
CD20+ B-lymphocytes [25-28]. Data from animal models
of papillomavirus infection suggest that APCs take up
virus-like-particles through the FcγRIII receptor [29],
degrade antigen within proteasomes and incorporate it
into MHC II on the cell surface. Thereafter, APCs trigger
the T cell-mediated adaptive response of CD4+ and CD8+
populations [29,30], in part by the release of a typical
pattern of inflammatory cytokines such as interleukin-1β,
interleukin-12, tumour necrosis factor-α, and interleukin-6
[31]. In this study, the presence of human papillomavirus
markers in a subset of semen leukocytes from a cohort of
HPV-genitourinary infected patients has been documented.
Both HPV-16 E6 and L1 proteins co-localized with the viral
DNA. Notably, cells displaying molecular hallmarks of
HPV were frequently found to be CD20+ B-lymphocytes
and CD56+ natural killer-like (NK-like) cells, two leukocyte
populations recruited during viral infection. In addition,
in peripheral blood of 25% of patients, the presence of
HPV-bearing cells was found by FISH and further
confirmed by single-step PCR. In agreement with the
results observed in semen, DNA and protein markers of
HPV in peripheral blood were mainly associated with
CD20+ and CD56+ cells. It is possible that signals for viral
DNA and L1-protein could be likely due to the endocytic
uptake of virions, given that they are mostly observed as
punctate patterns in the cytoplasm. However, if this was
the case, virion endocytosis does not explain the detection
of E6 protein and it is highly unlikely that the observed E6
signal is an artefact since it is only seen in HPV DNA
positive cells. These evidences raise the hypothesis that
NK-like cells and B lymphocytes represent possible targets
of HPV, in according to previous studies [32,33]. In fact on
a side, Renoux et al. [32] showed by in vitro studies that
cytotoxic activity and cytokine production by NK cells
appeared to be linked to rapid HPV-VLP entry into these
cells by macropinocytosis. Since CD16 blockade inhibited
this process, the authors concluded that CD16 is necessary
for HPV–VLP internalization [32], even if a role for CD16
as a primary receptor for HPV infection has not yet been
demonstrated. On the other side, the competency of HPV
to be uptaken by B lymphocytes cannot be excluded. In
fact, this possibility is supported by the fact that heparan-
sulfate proteoglycans, theorised to potentially be one of the
primary receptors involved in HPV entry, are expressed by
B lymphocytes and are a requirement for normal cell
maturation, differentiation and function [33]. However,
recent studies suggested that HPV entry into target cells is
actually the result of a concerted interaction between
virus-capside proteins and more than one receptor on cell
surface like α6-integrin or annexin A2-heterotetramer
[34,35]. Thus further investigation will be necessary to
clarify this aspect.
It has been postulated that HPV in polymorphonuclear
cells may be involved in vertical transmission of the virus,
following the detection of HPV-DNA in reproductive and
placental cells, as well as in virgins, infants and children
[36,37]. Indeed, since HPV-DNA has been detected in
amniotic fluid [37], placenta and the umbilical cord [36],
the hematogenous route of chorionic and placental tissue
infection and subsequent spread to amniotic cells and
possible ingestion by the fetus has been hypothesized
[36,37]. Since sporadic fetal brain malformations (eg,
dysplasias) could be detected as early as 24 weeks gesta-
tion [38], it has been suggested the transplacental spread
of HPV16 as a plausible mechanism for entry into the
brain during early fetal cortical development, even in the
absence of overt clinical infection. Interestingly, HPV-16
protein expression has very recently been reported in
patients affected by focal cortical dysplasia type IIB
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(FCDIIB) [39]. In particular, HPV16-E6 protein was
robustly expressed in cerebral cortex specimens of all
FCDIIB patients examined, most notably in the cytoplasm
of balloon cells (BC). E6 protein signals were not detectable
in regions without BC or in control tissue specimens.
Moreover, E6 expression in BC displayed a strong
association with components of the mammalian target
of rapamycin complex 1-signalling pathway, whose
abnormal activation is linked to FCDIIB etiology [40].
Taken together, these observations pose an open ques-
tion regarding the meaning of HPV markers found in
distinct blood leukocyte populations as the result of
cell-mediated immunity or the involvement in virus
spreading from the original site of infection.
In addition to the low number of patients enrolled, the
main drawback of this study is represented by the
extremely low percentage of HPV positive leukocytes
recovered in seminal fluid and peripheral blood. A
possible reason for these findings is that semen immune
cells can become unproductively infected with HPV16
when trafficking through the seminal compartment in
HPV16-infected men, and these cells may traffic back into
circulation and be detected at low frequency in peripheral
blood. This condition limited our ability to isolate HPV
bearing leukocytes and further evaluate their infectiveness.
Thus a mechanistic explanation about how virus enters
circulating mononuclear cells remains an open question.
Moreover, the assessment of HPV DNA on peripheral
blood performed by INNO LiPA was not able to confirm
the results obtained by FISH and Single-step PCR analysis
(data not shown). A possible explanation of this discrep-
ancy may reside in the different method sensitiveness.
Conclusion
In conclusion, this is the first study reporting the presence
of HPV-antigens together with HPV-DNA in circulating
PBMC from male patients with HPV-16 infection of the
genitourinary-tract. This evidence raises major concerns
about the risk of developing cancers to distal organs.
Additional file
Additional file 1: Figure S1. A: Positive FISH staining for HPV-DNA and
immunofluorescence staining for HPV-16 E6 an L1 proteins in cultured
Caski cells infected with HPV 16. B: Positive immunofluorescence staining
for human CD45, CD20, CD4, CD8 and CD56 antigens performed in
isolated peripheral blood mononuclear cells.
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